Patent · US Active

Bispecific binding molecules binding to VEGF and Ang2

US11161916B2 · kind B2 · utility

1Cited by

4References

5Claims

0Family size

Assignee

Boehringer Ingelheim International GmbH · DE

Inventors

Andreas GSCHWIND · Ingelheim am Rhein, DE
Rene Georg OTT · Wien, AT
Joachim BOUCNEAU · Zevergem, BE
Marie-Ange Buyse · Merelbeke, BE
Erik Depla · Laarne, BE

Key dates

Filing date	Jul 18, 2019
Grant date	Nov 2, 2021
Priority date	—
Expiry date	Jul 18, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/94
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Bispecifc binding molecules binding to both VEGF and Ang2, preferably in the form of immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing the same and their use in the treatment of diseases that are associated with VEGF- and/or Ang2-mediated effects on angiogenesis are disclosed. Further, nucleic acids encoding bispecific binding molecules, host cells and methods for preparing same are also described.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.